Bruker (NASDAQ:BRKR) Releases FY 2026 Earnings Guidance

Bruker (NASDAQ:BRKR) updated its FY 2026 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of 2.100-2.150 for the period, compared to the consensus estimate of 2.120. The company issued revenue guidance of $3.6 billion-$3.6 billion, compared to the consensus revenue estimate of $3.6 billion.

Analyst Ratings Changes

A number of brokerages have commented on BRKR. Barclays lowered their target price on Bruker from $50.00 to $45.00 and set an “overweight” rating on the stock in a research note on Tuesday, April 14th. TD Cowen upgraded Bruker to a “hold” rating in a research note on Monday, April 13th. Weiss Ratings upgraded Bruker from a “sell (d)” rating to a “sell (d+)” rating in a research note on Friday, April 24th. Citigroup decreased their price target on Bruker from $53.00 to $40.00 and set a “neutral” rating for the company in a research note on Friday, February 13th. Finally, Guggenheim decreased their price target on Bruker from $58.00 to $50.00 and set a “buy” rating for the company in a research note on Monday, March 30th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, five have assigned a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Bruker presently has a consensus rating of “Hold” and a consensus price target of $49.38.

Bruker Stock Performance

BRKR opened at $38.01 on Wednesday. The company has a market cap of $5.79 billion, a PE ratio of -253.40, a price-to-earnings-growth ratio of 2.18 and a beta of 1.12. The stock has a 50-day moving average of $37.13 and a 200-day moving average of $41.99. Bruker has a 52-week low of $28.53 and a 52-week high of $56.22. The company has a debt-to-equity ratio of 0.75, a quick ratio of 0.87 and a current ratio of 1.73.

Bruker (NASDAQ:BRKR) last released its quarterly earnings results on Wednesday, May 6th. The medical research company reported $0.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.23 by $0.08. The company had revenue of $823.40 million during the quarter, compared to the consensus estimate of $796.11 million. Bruker had a positive return on equity of 13.56% and a negative net margin of 0.25%.Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. As a group, equities research analysts forecast that Bruker will post 2.12 earnings per share for the current fiscal year.

Bruker Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, April 7th. Investors of record on Monday, March 23rd were given a dividend of $0.05 per share. This represents a $0.20 annualized dividend and a dividend yield of 0.5%. The ex-dividend date of this dividend was Monday, March 23rd. Bruker’s payout ratio is currently -133.33%.

Insider Buying and Selling at Bruker

In related news, VP Mark Munch sold 2,000 shares of the business’s stock in a transaction dated Wednesday, April 15th. The stock was sold at an average price of $39.90, for a total transaction of $79,800.00. Following the completion of the transaction, the vice president owned 128,443 shares of the company’s stock, valued at approximately $5,124,875.70. The trade was a 1.53% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 27.20% of the company’s stock.

Hedge Funds Weigh In On Bruker

Large investors have recently made changes to their positions in the business. Los Angeles Capital Management LLC acquired a new position in shares of Bruker during the 4th quarter worth about $26,000. Parallel Advisors LLC lifted its position in shares of Bruker by 121.0% during the 4th quarter. Parallel Advisors LLC now owns 875 shares of the medical research company’s stock worth $41,000 after purchasing an additional 479 shares during the last quarter. Allworth Financial LP lifted its position in shares of Bruker by 40.6% during the 3rd quarter. Allworth Financial LP now owns 890 shares of the medical research company’s stock worth $29,000 after purchasing an additional 257 shares during the last quarter. Summit Securities Group LLC acquired a new position in shares of Bruker during the 4th quarter worth about $50,000. Finally, Parkside Financial Bank & Trust lifted its position in shares of Bruker by 144.6% during the 4th quarter. Parkside Financial Bank & Trust now owns 1,482 shares of the medical research company’s stock worth $70,000 after purchasing an additional 876 shares during the last quarter. Institutional investors and hedge funds own 79.52% of the company’s stock.

About Bruker

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.